multiple myeloma Clinical Trials and Research
Also known as: plasma cell myeloma, myelomatosis, kahler's disease, mm, multiple plasmacytoma · ICD-10: C90.0-
Multiple myeloma is a cancer affecting plasma cells in the bone marrow, leading to bone damage, kidney problems, and weakened immunity. Clinical trial research focuses on developing new treatments, improving diagnosis, and managing disease complications. Find a Trial helps patients and caregivers search for active studies.
Search multiple myeloma trials →
Common questions about multiple myeloma clinical trials
Who can participate in multiple myeloma clinical trials?
Eligibility criteria vary by study, often including age, disease stage, and overall health. Researchers use these criteria to ensure patient safety and collect relevant data, as seen on ClinicalTrials.gov.
What are the different phases of clinical trials for multiple myeloma?
Clinical trials progress through phases (1-4), each with specific goals, from testing safety in small groups to evaluating effectiveness in larger populations. This structured approach helps ensure new treatments are safe and effective, according to data from ClinicalTrials.gov.
Do multiple myeloma clinical trials cost money to participate?
Typically, study-related medical costs, such as investigational drugs and tests, are covered by the trial sponsor. However, other costs like travel or standard medical care may not be, as detailed on ClinicalTrials.gov.
What new treatments are being studied for multiple myeloma?
Current research, supported by NIH RePORTER, explores immunotherapies like CAR T-cell therapy and bispecific antibodies, as well as novel targeted agents. These studies aim to improve response rates and extend remission for patients.
What types of interventions are typically tested in multiple myeloma trials?
Trials often investigate new drug combinations, stem cell transplants, and radiation therapies. They also explore supportive care interventions to manage symptoms and improve quality of life, based on information from ClinicalTrials.gov.
Are there specific biomarkers relevant to multiple myeloma clinical trials?
Biomarkers like M-protein levels, beta-2 microglobulin, and specific genetic mutations are often monitored in trials. These help researchers assess disease activity, predict treatment response, and stratify patients, as indicated by NIH RePORTER data.
What might prevent someone from joining a multiple myeloma trial?
Common exclusion criteria can include significant heart or kidney problems, uncontrolled infections, or prior treatments that might interfere with the study drug. These criteria ensure patient safety and study integrity, as outlined on ClinicalTrials.gov.
Do multiple myeloma trials address quality of life?
Many clinical trials for multiple myeloma include endpoints to assess quality of life, symptom management, and side effect profiles. Researchers aim to develop treatments that not only extend life but also maintain or improve patient well-being, according to ClinicalTrials.gov.
How to find a multiple myeloma trial that fits you
- Describe your multiple myeloma situation in detail — stage if applicable, prior treatments, age, and other relevant conditions.
- Use the location filter (worldwide, US, US & Canada, Europe) to narrow to trials near you.
- Review each trial's eligibility criteria carefully. Save 2–5 candidates with their NCT numbers.
- Discuss with your treating clinician before contacting the research site.
Browse all multiple myeloma trials →